Cargando…

Survival of patients with stomach adenocarcinoma in North of Iran

Aim: This study was proposed for estimation of survival time in patients with stomach adenocarcinoma. Background: North of Iran has a high mortality rate of stomach adenocarcinoma. Patients and methods: The study was historical cohort. The samples were the patients with stomach adenocarcinoma referr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazdani-Charati, Jamshid, Janbabaei, Ghasem, Etemadinejad, Siavosh, Sadeghi, Samaneh, Haghighi, Firoozeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185875/
https://www.ncbi.nlm.nih.gov/pubmed/25289135
_version_ 1782337977975832576
author Yazdani-Charati, Jamshid
Janbabaei, Ghasem
Etemadinejad, Siavosh
Sadeghi, Samaneh
Haghighi, Firoozeh
author_facet Yazdani-Charati, Jamshid
Janbabaei, Ghasem
Etemadinejad, Siavosh
Sadeghi, Samaneh
Haghighi, Firoozeh
author_sort Yazdani-Charati, Jamshid
collection PubMed
description Aim: This study was proposed for estimation of survival time in patients with stomach adenocarcinoma. Background: North of Iran has a high mortality rate of stomach adenocarcinoma. Patients and methods: The study was historical cohort. The samples were the patients with stomach adenocarcinoma referred to Tooba Clinic between three years (2007-2010). Survival estimates were calculated using the Kaplan-Meier method the effects of covariates on survival time were assessed by, using survival parametric regression model with gamma frailty. Results: The survival probability of more than two years of patients was calculated 27.7% by using Kaplan Mayer method. The stage, metastasis, surgery, and age were the variables which affect the survival probability of patients, by using survival parametric regression model with gamma frailty and hazard ratio of patients with three treatment protocol was 0.43 times of others (P<0.01) and increasing of patients ages decrease life time of them significantly as per year increasing patient age, risk of death increased by 4% (P<0.04) and patients with staging disease lower 4 had hazard ratio lower than 0.46 times of stage 4 (P<0.01). Conclusion: The survival time of our patients is much lower than the developed countries, which are related to latency in diagnosis and therapeutic limitations.
format Online
Article
Text
id pubmed-4185875
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-41858752014-10-06 Survival of patients with stomach adenocarcinoma in North of Iran Yazdani-Charati, Jamshid Janbabaei, Ghasem Etemadinejad, Siavosh Sadeghi, Samaneh Haghighi, Firoozeh Gastroenterol Hepatol Bed Bench Original Article Aim: This study was proposed for estimation of survival time in patients with stomach adenocarcinoma. Background: North of Iran has a high mortality rate of stomach adenocarcinoma. Patients and methods: The study was historical cohort. The samples were the patients with stomach adenocarcinoma referred to Tooba Clinic between three years (2007-2010). Survival estimates were calculated using the Kaplan-Meier method the effects of covariates on survival time were assessed by, using survival parametric regression model with gamma frailty. Results: The survival probability of more than two years of patients was calculated 27.7% by using Kaplan Mayer method. The stage, metastasis, surgery, and age were the variables which affect the survival probability of patients, by using survival parametric regression model with gamma frailty and hazard ratio of patients with three treatment protocol was 0.43 times of others (P<0.01) and increasing of patients ages decrease life time of them significantly as per year increasing patient age, risk of death increased by 4% (P<0.04) and patients with staging disease lower 4 had hazard ratio lower than 0.46 times of stage 4 (P<0.01). Conclusion: The survival time of our patients is much lower than the developed countries, which are related to latency in diagnosis and therapeutic limitations. Shaheed Beheshti University of Medical Sciences 2014 /pmc/articles/PMC4185875/ /pubmed/25289135 Text en ©2014 RIGLD, Research Institute for Gastroenterology and Liver Diseases This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yazdani-Charati, Jamshid
Janbabaei, Ghasem
Etemadinejad, Siavosh
Sadeghi, Samaneh
Haghighi, Firoozeh
Survival of patients with stomach adenocarcinoma in North of Iran
title Survival of patients with stomach adenocarcinoma in North of Iran
title_full Survival of patients with stomach adenocarcinoma in North of Iran
title_fullStr Survival of patients with stomach adenocarcinoma in North of Iran
title_full_unstemmed Survival of patients with stomach adenocarcinoma in North of Iran
title_short Survival of patients with stomach adenocarcinoma in North of Iran
title_sort survival of patients with stomach adenocarcinoma in north of iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185875/
https://www.ncbi.nlm.nih.gov/pubmed/25289135
work_keys_str_mv AT yazdanicharatijamshid survivalofpatientswithstomachadenocarcinomainnorthofiran
AT janbabaeighasem survivalofpatientswithstomachadenocarcinomainnorthofiran
AT etemadinejadsiavosh survivalofpatientswithstomachadenocarcinomainnorthofiran
AT sadeghisamaneh survivalofpatientswithstomachadenocarcinomainnorthofiran
AT haghighifiroozeh survivalofpatientswithstomachadenocarcinomainnorthofiran